Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 52 of 110 Updated Nov 17, 2026

Ipamorelin

NNC 26-0161

ANECDOTAL + PHASE 2 · GROWTH HORMONE-RELEASING PEPTIDE (GHRP); GHRELIN RECEPTOR AGONIST

▓ 64 indexed citations across PubMed (42), ClinicalTrials.gov (3), EuropePMC (19).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

64 citations across 5 tiers

Tap any tier to jump to that section of the bibliography.

Background

Ipamorelin (INN; development code NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue. It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.

→ Wikipedia

Mechanism of action

Selective GHS-R1a (ghrelin receptor) agonist on pituitary; no cortisol or prolactin rise

Researched effects

Clean GH release without cortisol/prolactin rise; minimal hunger; lean mass; recovery

Live evidence

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

200 mcg SC 2x daily (Seeds Vol 1 starting protocol, range up to 300 mcg 3x daily per r/Peptides wiki, often stacked with CJC-1295 no-DAC)

→ Seeds WA, Peptide Protocols Vol 1 (ipamorelin TID starter); r/Peptides wiki BID/TID pre-meal stacking consensus

Known concerns

Mild fatigue; headache; injection site reactions; elevated IGF-1 theoretical

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.

    International journal of colorectal disease · 2014 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 73.4

  2. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function

    2011 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 72.1

  3. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.

    Pharmaceutical research · 1999 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 72.0

  4. Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus

    2008 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 71.8

  5. Trifecta Research Study

    2022 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 66.2

  6. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

    The American journal of sports medicine · 2026 — REVIEWS · AUTHORITY 54.5

  7. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance.

    Sports medicine (Auckland, N.Z.) · 2026 — REVIEWS · AUTHORITY 54.5

  8. Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives.

    International journal of molecular sciences · 2026 — REVIEWS · AUTHORITY 54.5

  9. Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Implications.

    JBJS reviews · 2026 — REVIEWS · AUTHORITY 54.5

  10. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.

    Translational andrology and urology · 2020 — REVIEWS · AUTHORITY 54.0

Full citation library

Year distribution

Randomised Controlled Trials

2
  1. 1.

    Gobburu JV, Agersø H, Jusko WJ, Ynddal L · Pharmaceutical research · 1999 · PMID 10496658

    To examine the pharmacokinetics (PK) and pharmacodynamics (PD) of ipamorelin, a growth hormone (GH) releasing peptide, in healthy volunteers. A trial was conducted with a dose escalation design comprising 5 different infusion rates (4.21, 14.02, 42.13, 84.27 and 140.45 nmol/kg over 15 minutes) with eight healthy male subjects at each dose level. Concentrations of ipamorelin and growth hormone were measured. The PK parameters showed dose-proportionality, with a short terminal half-life of 2 hours…

  2. 2.

    Beck DE, Sweeney WB, McCarter MD · International journal of colorectal disease · 2014 · PMID 25331030

    Postoperative ileus is a significant clinical challenge lacking effective management strategies. Ghrelin-receptor stimulation has promotility effects in the upper and lower gastrointestinal tract. This proof-of-concept, phase 2, randomized study evaluated the safety and efficacy of the ghrelin-receptor agonist ipamorelin in the treatment of postoperative ileus following abdominal surgery (ClinicalTrials.gov NCT00672074). The design was a multicenter, double-blind, placebo-controlled, clinical tr…

Trial Registrations (ClinicalTrials.gov)

3
  1. 3.

    NCT01280344 · Phase 2 · Completed · 2011

    Conditions: Gastrointestinal Dysmotility

  2. 4.

    NCT00672074 · Phase 2 · Completed · 2008

    Conditions: Ileus

  3. 5.

    NCT07717866 · Active Not Recruiting · 2022

    Conditions: PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury (+2)

Reviews

6
  1. 6.

    Mayfield CK, Bolia IK, Feingold CL, Lin EH, et al. · The American journal of sports medicine · 2026 · PMID 41476424

    Therapeutic peptides are short-chain amino acids that regulate cellular functions and facilitate biochemical processes. In recent years, there has been significant growth in the global market for therapeutic peptides and thus its popularity among patients. Given the increase in the development of peptides and increased marketing to patients for orthopaedic injuries, it is critical for orthopaedic surgeons to understand the current evidence behind these therapeutic peptides. To evaluate the curre…

  2. 7.

    Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, et al. · Translational andrology and urology · 2020 · PMID 32257855

    Male hypogonadism is an increasingly prevalent clinical condition that affects patients' quality of life and overall health. Obesity and metabolic syndrome can both cause and result from hypogonadism. Although testosterone remains the gold standard for hypogonadism management, its benefits are not always conserved across different populations, especially with regards to changes in body composition. Partially in response to this, growth hormone secretagogues (GHS) have emerged as a potential nove…

  3. 8.

    Mendias CL, Awan TM · Sports medicine (Auckland, N.Z.) · 2026 · PMID 41966639

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objecti…

  4. 9.

    Mavrych V, Shypilova I, Bolgova O · Frontiers in aging · 2026 · PMID 42021992

    Peptide therapeutics represent an emerging frontier in gerontological medicine, targeting fundamental hallmarks of aging including metabolic dysfunction, telomere attrition, tissue repair impairment, and hormonal decline. To comprehensively review the mechanisms, clinical applications, evidence base, and safety profiles of therapeutic peptides with demonstrated or potential applications in healthy aging and age-related conditions. A comprehensive narrative review was conducted through systematic…

  5. 10.

    Renke G, Chinellato L · International journal of molecular sciences · 2026 · PMID 42123471

    Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes. While several peptide drugs have undergone rigorous approval processes that evaluate both safety and efficacy, novel, unapproved compounds have emerged and are rapidly expanding into preventive medicine and performance enhancement. Our objective is to present the effects, clinical applications, safety profiles, and regulatory status of prominent peptides used…

  6. 11.

    Villegas Meza AD, Nocek M, Mitchell BC, Lizarraga M, et al. · JBJS reviews · 2026 · PMID 42160466

    Injectable peptides are increasingly promoted for musculoskeletal recovery, tissue repair, and performance enhancements; however, clinical adoption has outpaced high-quality evidence and regulatory consensus. To summarize contemporary human and translational evidence (January 1, 2020-August 31, 2025) for injectable peptides relevant to orthopaedics and sports medicine, and to clarify safety, product quality, regulatory, antidoping implications, and clinical outcomes. Structured narrative review.…

Research Articles

50
  1. 12.

    Johansen PB, Hansen KT, Andersen JV, Johansen NL · Xenobiotica; the fate of foreign compounds in biological systems · 1998 · PMID 9879640

    1. The pharmacokinetics of three new peptidyl growth hormone secretagogues, ipamorelin (NNC 26-0161), NNC 26-0194 and NNC 26-0235, were compared with two well-known hexapeptides, GHRP-2 and GHRP-6, in the male rat following different routes of administration. 2. Following i.v. bolus injection, plasma concentrations of the peptides declined biexponentially. Ipamorelin differed markedly from the other peptides investigated, demonstrating a systemic plasma clearance 5-fold lower than that of GHRP-6…

  2. 13.

    Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2018 · PMID 29864719

    Detecting agents allegedly or evidently promoting growth such as human growth hormone (GH) or growth hormone releasing peptides (GHRP) in doping controls has represented a pressing issue for sports drug testing laboratories. While GH is a recombinant protein with a molecular weight of 22 kDa, the GHRPs are short (3-6 amino acids long) peptides with GH releasing properties. The endogenously produced GH (22 kDa isoform) consists of 191 amino acids and has a monoisotopic molecular mass of 22,124 Da…

  3. 14.

    Johansen PB, Nowak J, Skjaerbaek C, Flyvbjerg A, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999 · PMID 10373343

    Ipamorelin is a new and potent synthetic pentapeptide which has distinct and specific growth hormone (GH)-releasing properties. With the objective of investigating the effects on longitudinal bone growth rate (LGR), body weight (BW), and GH release, ipamorelin in different doses (0, 18, 90 and 450 microg/day) was injected s.c. three times daily for 15 days to adult female rats. After intravital tetracycline labelling on days 0, 6, and 13, LGR was determined by measuring the distance between the…

  4. 15.

    N Mohammadi E, Louwies T, Pietra C, Northrup SR, et al. · Journal of experimental pharmacology · 2020 · PMID 32801950

    The anti-nociceptive properties of ghrelin have been demonstrated in alleviating inflammatory and neuropathic pain. Whether a ghrelin receptor-mediated mechanism attenuates visceral and somatic pain in the absence of active inflammation remains to be explored. Here, we investigate the efficacy of peripherally restricted (ipamorelin) and a globally active (HM01) selective ghrelin receptor agonist in an experimental model of non-inflammatory visceral hypersensitivity and somatic mechanical allodyn…

  5. 16.

    Aagaard NK, Grøfte T, Greisen J, Malmlöf K, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2009 · PMID 19231263

    Growth hormone (GH) reduces the catabolic side effects of steroid treatment via effects on the amino-nitrogen metabolism. Ipamorelin is a synthetic peptide with GH releasing properties. We wished to study the metabolic effects of Ipamorelin and GH on selected hepatic measures of alpha-amino-nitrogen conversion during steroid-induced catabolism. Five groups of rats were included: (1) free-fed controls (2) pair-fed controls (3) prednisolone (delcortol, 4 mg x kg(-1) x day(-1)) (4) prednisolone and…

  6. 17.

    Lu Z, Ngan MP, Liu JYH, Yang L, et al. · Physiology & behavior · 2024 · PMID 39043357

    This study investigated whether ghrelin mimetics, namely anamorelin and ipamorelin, can alleviate weight loss and inhibition of feeding observed during acute and delayed phases of cisplatin-induced emesis in ferrets. The potential of anamorelin to inhibit electrical field stimulation (EFS)-induced contractions of isolated ferret ileum was compared with ipamorelin. In other experiments, ferrets were administered anamorelin (1-3 mg/kg), ipamorelin (1-3 mg/kg), or vehicle intraperitoneally (i.p.) 3…

  7. 18.

    Jiménez-Reina L, Cañete R, de la Torre MJ, Bernal G · Histology and histopathology · 2002 · PMID 12168778

    Growth hormone (GH) is secreted in the anterior pituitary gland by the somatotroph cells. Secretion is regulated by growth hormone releasing hormone (GHRH) and somatostatin. Morever, GH secretagogues (GHS) can exert a considerable effect on GH secretion. In order to determine the effects of chronic treatment with the GHS Ipamorelin on the composition of the somatotroph cell population and on somatotroph GH content, an in vitro analysis was performed of the percentage of somatotroph cells (% of t…

  8. 19.

    Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B · The Journal of pharmacology and experimental therapeutics · 2009 · PMID 19289567

    Ghrelin and ghrelin mimetics stimulate appetite and enhance gastric motility. The present study investigates whether ipamorelin, a selective growth hormone secretagogue and agonist of the ghrelin receptor, would accelerate gastrointestinal transit and ameliorate the symptoms in a rodent model of postoperative ileus (POI). Fasted male rats were subjected to laparotomy and intestinal manipulation. At the end of surgery, a dye marker was infused in the proximal colon to evaluate postsurgical coloni…

  9. 20.

    Ankersen M, Johansen NL, Madsen K, Hansen BS, et al. · Journal of medicinal chemistry · 1998 · PMID 9733495

    A new series of GH secretagogues derived from ipamorelin is described. In an attempt to obtain oral bioavailability, by reducing the size and the number of potential hydrogen-bonding sites of the compounds, a strategy using the peptidomimetic fragment 3-(aminomethyl)benzoic acid and sequential backbone N-methylations was applied. Several compounds from this series release GH with high in vitro potency and efficacy in a rat pituitary cell assay and high in vivo potency and efficacy in anesthetize…

  10. 21.

    Raun K, Hansen BS, Johansen NL, Thøgersen H, et al. · European journal of endocrinology · 1998 · PMID 9849822

    The development and pharmacology of a new potent growth hormone (GH) secretagogue, ipamorelin, is described. Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), which displays high GH releasing potency and efficacy in vitro and in vivo. As an outcome of a major chemistry programme, ipamorelin was identified within a series of compounds lacking the central dipeptide Ala-Trp of growth hormone-releasing peptide (GHRP)-1. In vitro, ipamorelin released GH from primary rat pituitary cells wi…

  11. 22.

    Andersen NB, Malmlöf K, Johansen PB, Andreassen TT, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 2001 · PMID 11735244

    The ability of the growth hormone secretagogue (GHS) Ipamorelin to counteract the catabolic effects of glucocorticoid (GC) on skeletal muscles and bone was investigated in vivo in an adult rat model. Groups of 8-month-old female rats were injected subcutaneously for 3 months with GC (methylprednisolone) 9 mg/kg/day or GHS (Ipamorelin) 100 microg/kg three times daily, or both GC and GHS in combination. The maximum tetanic tension of the calf muscles was determined in vivo in a materials testing m…

  12. 23.

    Lall S, Tung LY, Ohlsson C, Jansson JO, et al. · Biochemical and biophysical research communications · 2001 · PMID 11162489

    Growth hormone secretagogues (GHSs) stimulate growth hormone (GH) secretion, which is lipolytic. Here we compared the effects of twice daily s.c. treatment of GH and the GHS, ipamorelin, on body fat in GH-deficient (lit/lit) and in GH-intact (+/lit and +/+) mice. In +/lit and lit/lit mice ipamorelin induced a small (15%) increase in body weight by 2 weeks, that was not further augmented by 9 weeks. GH treatment markedly enhanced body weight in both groups. Ipamorelin also increased fat pad weigh…

  13. 24.

    Adeghate E, Ponery AS · Neuro endocrinology letters · 2004 · PMID 15665799

    To examine the effect of ipamorelin (IPA), a novel pentapeptide with a strong growth hormone releasing potency, on insulin secretion from pancreatic tissue fragments of normal and diabetic rats. Diabetes mellitus was induced by streptozotocin (60 mg kg(-1)). Four weeks after the induction of diabetes, pancreatic tissue fragments of normal and diabetic rats were removed and incubated with different concentrations (10(-12) - 10(-6) M) of IPA. Insulin release from the pancreas was measured by radio…

  14. 25.

    Hansen TK, Ankersen M, Hansen BS, Raun K, et al. · Journal of medicinal chemistry · 1998 · PMID 9733496

    A novel class of growth hormone-releasing compounds with a molecular weight in the range from 500 to 650 has been discovered. The aim of this study was to obtain growth hormone secretagogues with oral bioavailability. By a rational approach we were able to reduce the size of the lead compound ipamorelin (4) and simultaneously to reduce hydrogen-bonding potential by incorporation of backbone isosters while retaining in vivo potency in swine. A rat pituitary assay was used for screening of all com…

  15. 26.

    Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C · Journal of experimental pharmacology · 2012 · PMID 27186127

    Delayed gastric emptying is a common disorder with few effective therapeutic options. The goal of this study was to investigate whether ipamorelin, a synthetic peptidomimetic that acts on the ghrelin receptor, accelerates gastric emptying in a rodent model of gastroparesis induced by abdominal surgery and intestinal manipulation. Fasted adult male rats were subjected to laparotomy and intestinal manipulation. Following the surgery rats received ipamorelin (0.014-0.14 µmol/kg) or vehicle control…

  16. 27.

    Ferro P, Krotov G, Zvereva I, Rodchenkov G, et al. · Drug testing and analysis · 2017 · PMID 26811125

    Growth hormone releasing peptides (GHRPs) could be widely used by cheating athletes because they produce growth hormone (GH) secretion, so may generate an ergogenic effect in the body. Knowledge of the essential amino acids needed in GHRP structure for interaction with the target biological receptor GHSR1a, the absorption through different administration routes, and the maintenance of pharmacological activity of potential biotransformation products may help in the fight against their abuse in sp…

  17. 28.

    Gouda M, Ganesh CB · Animal reproduction science · 2024 · PMID 38996787

    Ghrelin, a peptide found in the brain and gut, is predicted to play a significant role in the control of various physiological systems in fish. The objective of this study was to examine the impact of ipamorelin acetate (IPA), a ghrelin agonist, on the reproductive axis of the tilapia Oreochromis mossambicus. The administration of either 5 or 30 µg of IPA for 21 days led to a significant and dose-dependent rise in food intake concomitant with a significant increase in the numbers of primary sper…

  18. 29.

    Gajda PM, Holm NB, Hoej LJ, Rasmussen BS, et al. · Drug testing and analysis · 2019 · PMID 30136411

    A number of unknown pharmaceutical preparations seized by Danish customs authorities were submitted for liquid chromatography-high resolution mass spectrometry (LC-HRMS) analysis. Comparison with reference standards unequivocally identified the content of the powders as analogs of the growth hormone secretagogues GHRP-2 (Pralmorelin), GHRP-6, Ipamorelin, and modified growth hormone releasing factor (modified GRF 1-29), which can be used as performance-enhancing substances in sports. In all cases…

  19. 30.

    Svensson J, Lall S, Dickson SL, Bengtsson BA, et al. · The Journal of endocrinology · 2000 · PMID 10828840

    Growth hormone (GH) is of importance for normal bone remodelling. A recent clinical study demonstrated that MK-677, a member of a class of GH secretagogues (GHSs), increases serum concentrations of biochemical markers of bone formation and bone resorption. The aim of the present study was to investigate whether the GHSs, ipamorelin (IPA) and GH-releasing peptide-6 (GHRP-6), increase bone mineral content (BMC) in young adult female rats. Thirteen-week-old female Sprague-Dawley rats were given IPA…

  20. 31.

    Hansen TK, Ankersen M, Raun K, Hansen BS · Bioorganic & medicinal chemistry letters · 2001 · PMID 11459660

    A series of NN703 analogues with lysine mimetics combined with naphthyl- or biphenylalanine in the core has been prepared and tested in vitro in a rat pituitary cell based assay and subsequently in vivo in pigs in a single dose at 50 nmol/kg. Re-introduction of certain pharmacophores in the C-terminal of NN703, which were originally removed during optimisation for oral bioavailability, led to unexpectedly potent compounds in vitro as well as in vivo.

  21. 32.

    Semenistaya E, Zvereva I, Thomas A, Thevis M, et al. · Drug testing and analysis · 2015 · PMID 25869809

    Growth hormone releasing peptides (GHRPs) stimulate secretion of endogenous growth hormone and are listed on the World Anti-Doping Agency (WADA) Prohibited List. To develop an effective method for GHRPs anti-doping control we have investigated metabolites of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin in urine after nasal administration. Each compound was administrated to one volunteer. Samples were collected for 2 days after administration, processed by solid-phase extraction on weak cati…

  22. 33.

    Worm DJ, Els-Heindl S, Kellert M, Kuhnert R, et al. · Journal of peptide science : an official publication of the European Peptide Society · 2018 · PMID 30168238

    Boron neutron capture therapy (BNCT) is a binary cancer therapy, which combines the biochemical targeting of a boron-containing drug with the regional localization of radiation treatment. Although the concept of BNCT has been known for decades, the selective delivery of boron into tumor cells remains challenging. G protein-coupled receptors that are overexpressed on cancer cells in combination with peptidic ligands can be potentially used as shuttle system for a tumor-directed boron uptake. In t…

  23. 34.

    Johansen PB, Segev Y, Landau D, Phillip M, et al. · Experimental diabesity research · 2003 · PMID 14630569

    The growth hormone (GH) and insulin-like growth factor I (IGF-I) axis were studied in streptozotocin (STZ) diabetic and nondiabetic female mice following intravenous (IV) injection of the GH secretagogue (GHS) ipamorelin or saline. On day 14, blood samples were obtained before and 10 minutes after the injection. Livers were removed and frozen for determination of the mRNA expressions of the GH receptor, GH-binding protein, and IGF-I, and hepatic IGF-I peptide. Serum samples were analyzed for GH…

  24. 35.

    Thomas A, Delahaut P, Krug O, Schänzer W, et al. · Analytical chemistry · 2012 · PMID 23101768

    New, potentially performance enhancing compounds have frequently been introduced to licit and illicit markets and rapidly distributed via worldwide operating Internet platforms. Developing fast analytical strategies to follow these new trends is one the most challenging issues for modern doping control analysis. Even if reference compounds for the active drugs are readily obtained, their unknown metabolism complicates effective testing strategies. Recently, a new class of small C-terminally amid…

  25. 36.

    Semenistaya E, Zvereva I, Krotov G, Rodchenkov G · Drug testing and analysis · 2016 · PMID 26472487

    Currently liquid chromatography - mass spectrometry (LC-MS) analysis after solid-phase extraction (SPE) on weak cation-exchange cartridges is a method of choice for anti-doping analysis of small bioactive peptides such as growth hormone releasing peptides (GHRPs), desmoporessin, LHRH, and TB-500 short fragment. Dilution of urine samples with phosphate buffer for pH adjustment and SPE on weak cation exchange microelution plates was tested as a means to increase throughput of this analysis. Diluti…

  26. 37.

    Malmlöf K, Johansen PB, Haahr PM, Wilken M, et al. · Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society · 1999 · PMID 10629165

    The present study was undertaken to study the growth hormone-releasing properties and growth-promoting effect of a GH secretagogue ipamorelin (IPA) in rats given the synthetic glucocorticoid methylprednisolone (MP). In a first experiment, rats received either saline or MP (5.0 mg/kg) for 8 days. Treatment with MP significantly (P< 0.001) decreased body weight gain, but the acute response to either IPA or growth hormone releasing hormone (GHRH) in terms of plasma GH was not changed. In a second e…

  27. 38.

    Fowkes MM, Lalonde T, Yu L, Dhanvantari S, et al. · European journal of medicinal chemistry · 2018 · PMID 30282322

    The ghrelin receptor is a seven-transmembrane (7-TM) receptor known to have an increased level of expression in human carcinoma and heart failure. Recent work has focused on the synthesis of positron emission tomography (PET) probes designed to target and image this receptor for disease diagnosis and staging. However, these probes have been restricted to small-molecule quinalizonones and peptide derivatives of the endogenous ligand ghrelin. We describe the design, synthesis and biological evalua…

  28. 39.

    Chan CB, Fung CK, Fung W, Tse MC, et al. · Comparative biochemistry and physiology. Toxicology & pharmacology : CBP · 2004 · PMID 15556068

    The action of a number of growth hormone secretagogues (GHS) on growth hormone (GH) secretion and gene expression was studied in a primary culture of pituitary cells isolated from the black seabream Acanthopagrus schlegeli. The peptide GHS employed included growth hormone-releasing peptide (GHRP)-2, ipamorelin, and human ghrelin. The nonpeptide GHS employed included the benzolactam GHS L692,585 and the spiropiperidine GHS L163,540. Secreted GH was measured in the culture medium by an enzyme-link…

  29. 40.

    Thomas A, Walpurgis K, Krug O, Schänzer W, et al. · Journal of chromatography. A · 2012 · PMID 22901302

    In the present study, a screening assay was developed comprising 11 prohibited peptides (<1.5 kDa) that are sufficiently purified from urine using weak cation exchange with subsequent determination of all substances by means of nanoUHPLC separation coupled to high resolution tandem mass spectrometry. These peptides included Gonadorelin (LH-RH), Desmopressin and 9 growth hormone releasing peptides (GHRP-1, -2, -4, -5, -6, Hexarelin, Alexamorelin, Ipamorelin and a GHRP-2 metabolite); however, the…

  30. 41.

    Timms M, Hall N, Levina V, Vine J, et al. · Drug testing and analysis · 2014 · PMID 24574167

    The growth hormone releasing peptides (GHRPs) hexarelin, ipamorelin, alexamorelin, GHRP-1, GHRP-2, GHRP-4, GHRP-5, and GHRP-6 are all synthetic met-enkephalin analogues that include unnatural D-amino acids. They were designed specifically for their ability to stimulate growth hormone release and may serve as performance enhancing drugs. To regulate the use of these peptides within the horse racing industry and by human athletes, a method is presented for the extraction, derivatization, and detec…

  31. 42.

    Kwok WH, Ho EN, Lau MY, Leung GN, et al. · Analytical and bioanalytical chemistry · 2013 · PMID 23318763

    In recent years, there has been an ongoing focus for both human and equine doping control laboratories on developing detection methods to control the misuse of peptide therapeutics. Immunoaffinity purification is a common extraction method to isolate peptides from biological matrices and obtain sufficient detectability in subsequent instrumental analysis. However, monoclonal or polyclonal antibodies for immunoaffinity purification may not be commercially available, and even if available, such an…

  32. 43.

    Thomas A, Höppner S, Geyer H, Schänzer W, et al. · Analytical and bioanalytical chemistry · 2011 · PMID 21298258

    A family of small peptides has reached the focus of doping controls representing a comparably new strategy for cheating sportsmen. These growth hormone releasing peptides (GHRP) are orally active and induce an increased production of endogenous growth hormone (GH). While the established test for exogenous GH fails, the misuse of these prohibited substances remains unrecognized. The present study provides data for the efficient extraction of a variety of known drug candidates (GHRP-1, GHRP-2, GHR…

  33. 44.

    Peschke B, Ankersen M, Bauer M, Hansen TK, et al. · European journal of medicinal chemistry · 2002 · PMID 12204475

    In order to obtain more potent growth hormone secretagogues, a comparison of ipamorelin and NN703 suggested the addition of a polar group at the C-terminus of NN703. A study was conducted using constrained amines for this purpose. Here, substituted 4-piperidinylamino- and 4-dimethylaminopiperidino-substituents were found to give the most active compounds. A replacement of the 4-dimethylaminopiperidino-substituent with 4-hydroxypiperidino resulted in a series of compounds, which showed in vitro a…

  34. 45.

    Králík F, Kvíčalová A, Salaďáková A, Kuchař M, Setnička V. · 2026 · PMID 41555539

    Growth hormone-releasing peptides (GHRPs) comprise a group of small synthetic peptides that can effectively influence growth hormone secretion both in humans and animals. As many health conditions are associated with growth hormone dysregulation, this class of compounds seems to be good candidates for various therapeutic purposes. However, GHRPs are also associated with doping in professional sports and they have been abused by amateur sportsmen and bodybuilders as well. In the present work, we…

  35. 46.

    Lange T, Thomas A, Walpurgis K, Thevis M. · 2020 · PMID 32300840

    The added value of dried blood spot (DBS) samples complementing the information obtained from commonly routine doping control matrices is continuously increasing in sports drug testing. In this project, a robotic-assisted non-destructive hematocrit measurement from dried blood spots by near-infrared spectroscopy followed by a fully automated sample preparation including strong cation exchange solid-phase extraction and evaporation enabled the detection of 46 lower molecular mass (< 2 kDa) peptid…

  36. 47.

    Mosińska P, Zatorski H, Storr M, Fichna J. · 2017 · PMID 28238253

    There is an unmet need for effective pharmacological therapies for constipation, a symptom that significantly deteriorates patients' quality of life and impacts health care. Ghrelin is an endogenous ligand for the growth hormone secretagogue receptor and has been shown to exert prokinetic effects on gastrointestinal (GI) motility via the vagus and pelvic nerves. The pharmacological potential of ghrelin is hampered by its short half-life. Ghrelin receptor (GRLN-R) agonists with enhanced pharmacok…

  37. 48.

    Thevis M, Kuuranne T, Geyer H. · 2026 · PMID 41702393

    Alongside the considerable advances and accomplishments in drug research and development, the breadth of anti-doping research topics has also continued to grow. This is particularly relevant not only to provide comprehensive information on new drug entities, drug metabolism and elimination, and/or the impact of administration and exposure routes on analytical test results but also to ensure the timely implementation of analytical methods that ensure the availability of relevant anti-doping testi…

  38. 49.

    GARCIA RUBIO SILVINA, BEIDLER DANIEL E, WEIBEL HELLE, BRAGLIA RICCARDO. · 2010

    Injection and infusion solutions of ipamorelin, having the following composition: a) ipamorelin solubilized by approximately two molar equivalents of acetic acid (ipamorelin diacetate), in an amount of from 0.001 to 20%, based on the weight of the free base of ipamorelin b) a molar excess of acid, preferably acetic acid, in an amount sufficient to give a pH of at least 3 and less than 7 c) optionally from 0.1 to 30% of one or more formulation aids and d) water q.s. to 100% all percentages based…

  39. 50.

    RUBIO SILVINA GARCIA, BEIDLER DANIEL, WEIBEL HELLE, BRAGLIA RICCARDO. · 2010

    Injection and infusion solutions of ipamorelin, having the following composition: a) ipamorelin solubilized by approximately two molar equivalents of acetic acid (ipamorelin diacetate), in an amount of from 0.001 to 20%, based on the weight of the free base of ipamorelin b) a molar excess of acid, preferably acetic acid, in an amount sufficient to give a pH of at least 3 and less than 7 c) optionally from 0.1 to 30% of one or more formulation aids and d) water q.s. to 100% all percentages based…

  40. 51.

    SILVINA GARCIA RUBIO, DANIEL BEIDLER, HELLE WEIBEL, RICCARDO BRAGLIA. · 2012

    Injection and infusion solutions of ipamorelin, having the following composition: a) ipamorelin solubilized by approximately two molar equivalents of acetic acid (ipamorelin diacetate), in an amount of from 0.001 to 20%, based on the weight of the free base of ipamorelin b) a molar excess of acid, preferably acetic acid, in an amount sufficient to give a pH of at least 3 and less than 7 c) optionally from 0.1 to 30% of one or more formulation aids and d) water q.s. to 100% all percentages based…

  41. 52.

    POLVINO WILLIAM J, NELSON RICHARD, MANN WILLIAM R. · 2012

    The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a…

  42. 53.

    GARCIA RUBIO SILVINA, BEIDLER DANIEL, WEIBEL HELLE, BRAGLIA RICCARDO. · 2012

  43. 54.

    GARCIA RUBIO SILVINA, BEIDLER DANIEL, WEIBEL HELLE, BRAGLIA RICCARDO. · 2012

  44. 55.

    POLVINO WILLIAM J, NELSON RICHARD, MANN WILLIAM R. · 2010

  45. 56.

    MANN WILLIAM R, NELSON RICHARD, POLVINO WILLIAM J. · 2009

  46. 57.

    POLVINO WILLIAM J, NELSON RICHARD, MANN WILLIAM R. · 2009

    The present invention provides a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders, diseases, conditions, or drug- or surgery-induced dysfunction) of the gastrointestinal system, by administering to the subject a ghrelin mimetic, or pharmaceutically acceptable salt thereof. The invention also provides a method of treating a gastrointestinal malady by co-administering a ghrelin mimetic with a…

  47. 58.

    POLVINO WILLIAM J, NELSON RICHARD, MANN WILLIAM R. · 2010

  48. 59.

    Thevis M, Kuuranne T, Geyer H. · 2025 · PMID 39731401

    The 17th edition of the annual banned-substance review on analytical approaches in human sports drug testing is dedicated to literature published between October 2023 and September 2024. As in previous years, focus is put particularly on new or enhanced analytical options in human doping controls as well as investigations into the metabolism and elimination of compounds of interest, which represent central (while not exclusive) cornerstones of the global anti-doping mission. New information publ…

  49. 60.

    Childs MD, Luyt LG. · 2020 · PMID 33104445

    The growth hormone secretagogue receptor 1a (GHSR), also called the ghrelin receptor, is a G protein-coupled receptor known to play an important metabolic role in the regulation of various physiological processes, including energy expenditure, growth hormone secretion, and cell proliferation. This receptor has been implicated in numerous health issues including obesity, gastrointestinal disorders, type II diabetes, and regulation of body weight in patients with Prader-Willi syndrome, and there h…

  50. 61.

    Tewari K, Liu TP, Im C, Hamad C, et al. · The American journal of sports medicine · 2026 · PMID 42578445

    The peptide supplement market has experienced rapid growth due to marketing claims of enhanced performance and accelerated recovery from musculoskeletal injury. These peptides are increasingly popular with patients and athletes and are often perceived as low risk, despite the absence of efficacy or safety data for many emerging peptides. To summarize existing peer-reviewed data on 6 emerging peptides (BPC-157, thymosin beta-4 or TB-500, CJC-1295, MK-677, ipamorelin, and GHK-Cu [copper peptide])…

Preprints (not yet peer-reviewed)

3
  1. 62.

    Mendias CL, Awan TM. · 2026

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  2. 63.

    Mendias CL, Awan TM. · 2026

    Peptides are a rapidly expanding drug class with a parallel and largely unregulated gray market that sells preparations directly to consumers for self-administration. The use of gray market peptides has grown substantially, with patients self-administering these compounds for purported benefits including accelerated musculoskeletal injury recovery, muscle hypertrophy, fat loss, and athletic performance enhancement. The objective of this study was to evaluate the purity, measured abundance, and e…

  3. 64.

    Mendias CL, Awan TM. · 2025

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

Curated sources on file

9
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.

Continue reading